Stockreport

TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones

TCR2 Therapeutics Inc.  (TCRR) 
Last tcr2 therapeutics inc. earnings: 11/12 07:00 am Check Earnings Report
PDF - Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x108 cells/m2- Initiation of gavo-cel Phase 2 study expected in 1H 2022 with initial d [Read more]